Wim Criekinge - MDxHealth Chief Officer
| MDXH Stock | USD 1.96 0.02 1.03% |
Insider
Wim Criekinge is Chief Officer of MDxHealth SA ADR
| Age | 52 |
| Address | CAP Business Center, Herstal, Belgium, 4040 |
| Phone | 32 4 257 70 21 |
| Web | https://mdxhealth.com |
MDxHealth Management Efficiency
The company has return on total asset (ROA) of (0.1102) % which means that it has lost $0.1102 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4082) %, meaning that it created substantial loss on money invested by shareholders. MDxHealth's management efficiency ratios could be used to measure how well MDxHealth manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.93. The current Return On Capital Employed is estimated to decrease to -0.26. As of now, MDxHealth's Intangible Assets are increasing as compared to previous years. The MDxHealth's current Intangibles To Total Assets is estimated to increase to 0.65, while Other Current Assets are projected to decrease to under 1.5 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| RPh PharmD | Elevation Oncology | 40 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Valerie MD | Elevation Oncology | 46 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Gregory Flesher | Eledon Pharmaceuticals | 54 | |
| Russell MS | Acumen Pharmaceuticals | 65 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| David Hovland | Eledon Pharmaceuticals | N/A | |
| Demetrios MD | Inozyme Pharma | N/A | |
| David Dornan | Elevation Oncology | 46 | |
| Jeffrey Bornstein | Eledon Pharmaceuticals | N/A | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| MA MS | Inozyme Pharma | N/A | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -2.41 | ||||
| Return On Asset | -0.11 |
MDxHealth SA ADR Leadership Team
Elected by the shareholders, the MDxHealth's board of directors comprises two types of representatives: MDxHealth inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MDxHealth. The board's role is to monitor MDxHealth's management team and ensure that shareholders' interests are well served. MDxHealth's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MDxHealth's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wim Criekinge, Chief Officer | ||
| Joseph Sollee, Executive Counsel | ||
| Ron CPA, Chief Officer | ||
| John Bellano, Chief Officer | ||
| Jason Poole, Chief Officer | ||
| Miriam Reyes, Executive Operations | ||
| Paul Marr, Ex America | ||
| Ron Kalfus, Chief Officer | ||
| Michael McGarrity, CEO Director | ||
| LLM JD, Executive Counsel |
MDxHealth Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MDxHealth a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.41 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 103.08 M | ||||
| Shares Outstanding | 49.5 M | ||||
| Shares Owned By Insiders | 12.20 % | ||||
| Shares Owned By Institutions | 48.65 % | ||||
| Number Of Shares Shorted | 16.22 K | ||||
| Price To Book | 5.71 X |
Currently Active Assets on Macroaxis
When determining whether MDxHealth SA ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MDxHealth's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mdxhealth Sa Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mdxhealth Sa Adr Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MDxHealth SA ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MDxHealth. If investors know MDxHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MDxHealth listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share 3.099 | Quarterly Revenue Growth 0.205 | Return On Assets (0.11) | Return On Equity (2.41) |
The market value of MDxHealth SA ADR is measured differently than its book value, which is the value of MDxHealth that is recorded on the company's balance sheet. Investors also form their own opinion of MDxHealth's value that differs from its market value or its book value, called intrinsic value, which is MDxHealth's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MDxHealth's market value can be influenced by many factors that don't directly affect MDxHealth's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MDxHealth's value and its price as these two are different measures arrived at by different means. Investors typically determine if MDxHealth is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MDxHealth's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.